Shares of AVITA Medical (ASX:AVH) rose nearly 2% in recent Friday trade after the company said in a Thursday statement that the data from the US national burn registry showed the use of its cell harvesting device RECELL reduced hospital stays by an average of 36% compared to traditional skin grafts in adult patients with second-degree burns.
The data also showed potential cost savings of over $42,000 per patient, and suggested that shorter hospital stays could allow hospitals to treat 13 more patients per bed each year.